Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carbetocin (Primary)
Indications Prader-Willi syndrome
Focus Registrational; Therapeutic Use
Acronyms COMPASS PWS
Sponsors Acadia Pharmaceuticals

Most Recent Events

24 Sep 2025 Primary endpoint (Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score) has been met, according to the Top-line results published in the ACADIA Pharmaceuticals Media Release.
24 Sep 2025 Top-line results published in the ACADIA Pharmaceuticals Media Release
08 Aug 2025 Planned End Date changed from 1 Jun 2026 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com